Clues to quality of journals
Open Access Policy of Helmholtz Association 2016
CC Licencences
Publication Metrics
Home
Deutsch
New EVA Application
Advanced Search
Browse by ...
Publication overview
Statistics (last 5 years)
OA Publications
Submit Publication
Import publication from...
Report missing publication
Contact persons
Help
Text
Endnote (RIS)
BibTeX
PMC
 |
|
Open Access Green as soon as Postprint is submitted to ZB.
Histone deacetylase as a therapeutic target.
Trends Endocrinol. Metab. 12, 294-300 (2001)
The maintenance of health depends on the coordinated and tightly regulated expression of genetic information. Certain forms of leukemia have become paradigms for the pathogenic role of aberrant repression of differentiation genes. In these acute leukemias, fusion proteins generated by chromosomal translocations no longer function as transcriptional activators, but instead repress target genes by recruiting histone deacetylases (HDACs). The potential benefit of HDAC inhibition has been established by the use of enzyme inhibitors in vitro and in a single reported case of experimental therapy. Because recently identified HDAC inhibitors appear to overcome many drawbacks of early inhibitory compounds in clinical use, the stage is set to test the therapeutic value of HDAC inhibition in leukemias and in other diseases, including solid tumors and aberrant hormonal signaling. This review summarizes the range of diseases expected to respond to HDAC inhibition.
Impact Factor
Scopus SNIP
Altmetric
0.000
0.000
Annotations
Special Publikation
Hide on homepage
Publication type
Article: Journal article
Document type
Scientific Article
Language
english
Publication Year
2001
HGF-reported in Year
0
ISSN (print) / ISBN
1043-2760
e-ISSN
1879-3061
Quellenangaben
Volume: 12,
Issue: 7,
Pages: 294-300
Publisher
Elsevier
Reviewing status
Peer reviewed
PubMed ID
11504668
Erfassungsdatum
2001-12-31